Comparing CNBX Pharmaceuticals and BioRestorative Therapies

Analyzing the institutional and insider ownership of the two OTC-traded biotech companies

Published on Feb. 11, 2026

This article compares the institutional and insider ownership of CNBX Pharmaceuticals (OTCMKTS:CNBX) and BioRestorative Therapies (OTCMKTS:BRTX), two OTC-traded biotech companies. The data shows that CNBX Pharmaceuticals has significantly higher institutional and insider ownership compared to BioRestorative Therapies.

Why it matters

Strong institutional and insider ownership is generally seen as a positive indicator, suggesting that major investors and company insiders believe the stock is poised for long-term growth. This data provides insight into the market's perception and confidence in the two biotech companies.

The details

The data shows that 98.2% of CNBX Pharmaceuticals shares are held by institutional investors, compared to 69.4% for BioRestorative Therapies. Additionally, 73.5% of CNBX Pharmaceuticals shares are held by company insiders, while only 30.8% of BioRestorative Therapies shares are held by insiders.

  • The data is from February 11, 2026.

The players

CNBX Pharmaceuticals Inc.

A clinical stage company that engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer.

BioRestorative Therapies, Inc.

A company that develops therapeutic products and medical therapies using cell and tissue protocols, with a focus on treating chronic back pain and metabolic disorders.

Got photos? Submit your photos here. ›

The takeaway

The significantly higher institutional and insider ownership of CNBX Pharmaceuticals compared to BioRestorative Therapies suggests that major investors and company insiders have greater confidence in CNBX's long-term growth potential. This data provides valuable insight for investors evaluating the two OTC-traded biotech companies.